Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15241103 | 1.00 | TDP1 (0.46) | TDP1LMNAALDH1A1GAATNF | |
| SCHEMBL15240556 | 1.00 | TDP1 (0.46) | TDP1LMNAALDH1A1GAATNF | |
| SCHEMBL16414776 | 0.88 | LMNA (0.50) | TDP1LMNAALDH1A1GAATNF | |
| SCHEMBL6364898 | 0.88 | TDP1 (0.52) | TDP1LMNAALDH1A1GAATNF | |
| SCHEMBL701159 | 0.86 | ALDH1A1 (0.44) | TDP1LMNAALDH1A1GAATNF | |
| SCHEMBL16601646 | 0.85 | KDM4E (0.41) | TDP1LMNAALDH1A1GAATNF | |
| SCHEMBL15537671 | 0.83 | TNF (0.46) | TDP1LMNAALDH1A1GAATNF | |
| SCHEMBL701650 | 0.82 | ALDH1A1 (0.52) | TDP1LMNAALDH1A1GAATP53 | |
| SCHEMBL701651 | 0.82 | ALDH1A1 (0.52) | TDP1LMNAALDH1A1GAATP53 | |
| SCHEMBL15240826 | 0.82 | ALDH1A1 (0.52) | TDP1LMNAALDH1A1GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295440-A1 | VIOLET EXCITABLE TANDEM DYES, AND METHODS FOR MAKING AND USING THE SAME | BECTON, DICKINSON AND COMPANY | 2023-09-21 | — | — | US | disclosed |
| EP-3044226-B1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3044226-B1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20160222021-A1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-04 | — | — | US | disclosed |
| EP-3044226-A1 | ARYL ETHER-BASE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2822952-B1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-06 | — | — | EP | disclosed |
| WO-2015038112-A1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-19 | — | — | WO | disclosed |
| US-8969564-B2 | Aryl ether-base kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140179725-A1 | Aryl Ether-Base Kinase Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-06-26 | — | — | US | disclosed |
| US-8703953-B2 | Aryl ether-base kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130237555-A1 | Aryl Ether-Base Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2003018789-A1 | ESTERASE EST4B1 OBTAINED FROM BACILLUS SUBTILIS | DEGUSSA AG (DE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179725-A1 | Aryl Ether-Base Kinase Inhibitors | AAK1, NCK1, ADCK1 | TDP1 1874/4885LMNA 3331/4885ALDH1A1 3028/4885 |
| US-20160222021-A1 | ARYL ETHER-BASE KINASE INHIBITORS | AAK1, NCK1, ADCK1 | TDP1 1874/4885LMNA 3331/4885ALDH1A1 3028/4885 |
| US-20130237555-A1 | Aryl Ether-Base Kinase Inhibitors | AAK1, NCK1, ADCK1 | TDP1 1874/4885LMNA 3331/4885ALDH1A1 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.